Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of nivolumab combined with metformin in pre-treated metastatic renal cell carcinoma
2019-004916-76Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and metformin in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC), sponsored by Policlinico Gemelli. Primary endpoint: Progression-free survival rate at 9 months. Started Oct 2020; status: terminated.
02
Drugs
nivolumabmetformin
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2019-004916-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004916-76.